RxDoctor Payments Data

Theresa Lanham, DO

Endocrinology, Diabetes & Metabolism · Owensboro, KYNPI 1972037208

Payments from drug & device makers

$2,231in general payments, 2019–2025

Across 125 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$453
  • Lilly USA, LLC$347
  • Amgen$251
  • Insulet Corporation$223
  • Medtronic$186
  • AstraZeneca$164
  • plus $607 from 13 others

What the payments were for

  • Food & beverage$2,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,231 in reported general payments places this provider in the 30th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky

Medicare billing

Part B allowed, 2024
$56,245
Medicare patients
184
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide294$296,896
MounjaroTirzepatide141$147,777
TrulicityDulaglutide81$89,450
JardianceEmpagliflozin114$87,109
JanuviaSitagliptin Phosphate65$46,483
Humulin R U-500 KwikpenInsulin Regular, Human28$44,099
RybelsusSemaglutide38$32,752
FarxigaDapagliflozin Propanediol44$31,499
Tresiba Flextouch U-100Insulin Degludec41$24,876
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$17,311
Tresiba Flextouch U-200Insulin Degludec16$16,928
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$14,877
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt15$12,760
Lantus SolostarInsulin Glargine,hum.Rec.Anlog103$12,667
Fiasp FlextouchInsulin Aspart (Niacinamide)11$11,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$453$329,648332 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$347$238,686235 claims
Boehringer IngelheimJardiance$35$87,109114 claims
AstraZenecaFarxiga$164$31,49944 claims
AbbVieSynthroid$33$4,01961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

Other endocrinology, diabetes & metabolism in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →